CVR Medical Corp. Announces Completion of 2022 1st Quarter Financial Statement
CVR Medical Corp. Announces Completion of 2022 1st Quarter Financial Statement
Vancouver, British Columbia--(Newsfile Corp. - July 20, 2022) - CVR Medical Corp. (TSXV: CVM) (OTCQB: CRRVF) ("CVR Medical" or the "Company" or "we") a Canadian listed and US based healthcare company in the medical device market is pleased to announce the completion and filing of its 2022 Q1 Financial Statement. The financial report is posted on SEDAR.
温哥華，不列顛哥倫比亞省-(Newsfile Corp.-2022年7月20日)-CVR Medical Corp.(TSXV：CVM)(OTCQB：CRRVF)(“CVR醫療“或”公司“或”我們)一家加拿大上市的美國醫療保健公司很高興地宣佈完成並提交了其2022年第一季度財務報表。財務報告發布在SEDAR上。
About CVR Medical
關於CVR醫療
CVR Medical Corp. is a healthcare company that operates in the medical device industry focused on the commercialization of its disruptive, proprietary Carotid Stenotic Scan device (the "CSS"). The CSS is a diagnostic tool that encompasses subsonic, infrasonic, and low frequency sound wave analysis technology. The CSS is a patented device designed to detect and measure carotid arterial stenosis. CVR Medical's shares are listed on the OTCQX under the symbol "CRRVF". The Company was previously listed for trading under the symbol "CVM". Additional information regarding the Company can be found in our recent filings with the SEDAR as well as the information maintained on our website at .
CVR醫療公司是一家在醫療設備行業運營的醫療保健公司，專注於其顛覆性的、專有的頸動脈狹窄掃描設備的商業化。CSSCss是一種包含亞聲、次聲和低頻聲波分析技術的診斷工具。css是一種旨在檢測和測量頸動脈狹窄的專利設備。CVR Medical的股票在OTCQX上市，代碼為“CRRVF”。該公司以前以“CVM”的代碼上市。有關公司的更多信息可在我們最近提交給SEDAR的文件中找到，以及在我們的網站上維護的信息。
ON BEHALF OF THE BOARD:
(signed) Paul Blunden, M.D.
President & Director
我謹代表董事會：
(簽名)保羅·布倫登，醫學博士
總裁與董事
For further information contact:
Paul Blunden, M.D., President/ Director
Email: info@cvrmed.com
如需進一步信息，請聯繫：
保羅·布倫登，醫學博士，總裁/董事
電子郵件：info@cvrmed.com
This press release contains forward-looking information that involves various risks and uncertainties regarding future events related to: trading on and dialogue with the Exchange, communications and negotiations with CVR Global, dialogue with certain advisors, the Term Sheet, the Proposed Restructuring, the Definitive Agreement, the License Agreement, the Review, certain corporate and securities law requirements, raising capital, the 2019 Audit and potential litigation. Such statements are subject to risks and uncertainties that may cause actual results, performance or developments to differ materially from those contained in the statements and are not guarantees of future performance of the Company. No assurance can be given that any of the events anticipated by the forward-looking statements will occur or, if they do occur, what benefits the Company will obtain from them. These forward-looking statements reflect management's current views and are based on certain expectations, estimates and assumptions which may prove to be incorrect. A number of risks and uncertainties could cause our actual results to differ materially from those expressed or implied by the forward-looking statements, including: (1) a failure or material setback in negotiations between the Company and CVR Global; (2) a failure of the Company to resume trading on the Exchange; (3) a failure of the Company to raise capital sufficient capital to relaunch the Company; (4) an inability to enter into a definitive agreement with CVR Global; (5)a downturn in general economic conditions in North America and internationally, (6) the inherent uncertainties and speculative nature associated with commercialization of technology and the practice of medicine;(7) a change in health regulations; (8) any number of events or causes which may delay or cease commercialization and development of the CSS Device; (9) the risk that the Company does not execute its business plan, (10) the risk of litigation between the Company and certain shareholders and the risk of litigation generally; (11) an inability to retain key employees, (12) am inability to finance operations and growth, (13) compliance with certain corporate and securities law requirements; and (14) other factors that are beyond the Company's control. These forward-looking statements are made as of the date of this news release and, except as required by law, the Company assumes no obligation to update these forward-looking statements, or to update the reasons why actual results differed from those projected in the forward-looking statements.
本新聞稿包含前瞻性信息，涉及與以下相關的未來事件的各種風險和不確定性：在交易所進行交易和對話、與CVR Global的溝通和談判、與某些顧問的對話、條款説明書、擬議的重組、最終協議、許可協議、審查、某些公司和證券法要求、籌集資本、2019年審計和可能的訴訟。此類陳述會受到風險和不確定因素的影響，這些風險和不確定因素可能會導致實際結果、業績或發展與陳述中包含的內容大不相同，也不能保證公司未來的業績。不能保證前瞻性陳述中預期的任何事件都會發生，或者如果發生了，公司將從中獲得什麼好處。這些前瞻性陳述反映了管理層目前的觀點，並基於某些預期、估計和假設，這些預期、估計和假設可能被證明是不正確的。許多風險和不確定因素可能導致我們的實際結果與前瞻性陳述中明示或暗示的結果大不相同，包括：(1)公司與CVR Global之間的談判失敗或重大挫折；(2)公司未能恢復在交易所的交易；(3)公司未能籌集足夠的資本重新啟動公司；(4)無法與CVR Global達成最終協議；(5)北美和國際總體經濟狀況低迷。, (6)與技術商業化和醫療實踐相關的固有不確定性和投機性；(7)衞生法規的變化；(8)可能推遲或停止CS設備商業化和開發的任何事件或原因；(9)公司不執行其業務計劃的風險；(10)公司與某些股東之間的訴訟風險以及總體訴訟風險；(11)無法留住關鍵員工；(12)無法為運營和增長融資；(13)遵守某些公司和證券法的要求；(十四)公司無法控制的其他因素。這些前瞻性陳述是在本新聞稿發佈之日作出的，除非法律另有要求，否則公司沒有義務更新這些前瞻性陳述，也沒有義務更新實際結果與前瞻性陳述中預測的結果不同的原因。
THE TSX VENTURE EXCHANGE INC. HAS NEITHER APPROVED NOR DISAPPROVED THE CONTENTS OF THIS PRESS RELEASE. NEITHER THE TSX VENTURE EXCHANGE NOR ITS REGULATION SERVICES PROVIDER (AS THAT TERM IS DEFINED IN THE POLICIES OF THE TSX VENTURE EXCHANGE) ACCEPTS RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.
多倫多證券交易所風險交易所公司。既沒有批准也沒有反對本新聞稿的內容。多倫多證券交易所創業板交易所及其監管服務提供商(該術語在多倫多證券交易所創業板交易所的政策中定義)均不對本新聞稿的充分性或準確性承擔責任。
To view the source version of this press release, please visit
要查看本新聞稿的源版本，請訪問
譯文內容由第三人軟體翻譯。